Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Vaccine

Volumn 25, Issue 34, 2007, Pages 6334-6340

  Hu, Mary C ^a   Jones, Taff ^b   Kenney, Richard T ^a   Barnard, Dale L ^c   Burt, David S ^b   Lowell, George H ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

Intranasal vaccine; Neutralizing antibody; Protection; SARS

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PROTOLLIN; RECOMBINANT VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN;

ADOLESCENT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINE PRODUCTION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DRUG COMBINATIONS; FEMALE; IMMUNIZATION; LIPOPOLYSACCHARIDES; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; SARS VIRUS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 34447647449     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.017     Document Type: Article

References (22)

1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al., SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1953-1966
2. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1967-1976
3. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al., SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
4. Rota P.A., Oberste S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
5. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
6. Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y., Hon C.C., et al. The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39). Exp Biol Med (Maywood) 228 7 (2003) 866-873
7. Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses. Vaccine 24 (2006) 652-661
8. Qu D., Zheng B., Yao X., Guan Y., Yuan Z.H., Zhong N.S., et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 23 7 (2005) 924-931
9. Jiang S., He Y., and Liu S. SARS vaccine development. Emerg Infect Dis 11 7 (2005) 1016-1020
10. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 (2006) 3624-3631
11. Woo P.C., Lau S.K., Tsoi H.W., Chen Z.W., Wong B.H., Zhang L., et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23 42 (2005) 4959-4968
12. Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., and van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203 2 (2004) 631-637
13. Lowell G.H., Burt D.S., White G., and Fries G. Proteosome™ technology for vaccines and adjuvants. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines. 3rd ed. (revised and expanded) (2004), Marcel Dekker, Inc., New York 271-282
14. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 10 (2006) 1625-1632
15. Jones T., Cyr S., Allard F., Bellerose N., Lowell G.H., and Burt D.S. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 22 27-28 (2004) 3691-3697
16. Mallett C.P., Hale T.L., Kaminski R.W., Larsen T., Orr N., Cohen D., et al. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 63 6 (1995) 2382-2386
17. Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., and Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 69 (2001) 4545-4553
18. Plante M., Jones T., Allard F., Torossian K., Gauthier J., St-Felix N., et al. Nasal immunization with subunit proteosome influenza vaccines induce serum HAI, mucosal IgA and protection against Influenza challenge. Vaccine 20 (2001) 218-225
19. Roberts A., Paddock C., Vogel L., Butler E., Zaki S., and Subbarao K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79 9 (2005) 5833-5838
20. Zakhartchouk A.N., Liu Q., Petric M., and Babiuk L.A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23 (2005) 4385-4391
21. Reed L.J., and Muench N. A simple method of estimating fifty per cent endpoints. Am J Hygiene 27 (1938) 493-497
22. Frasca D., Riley R.L., and Blomberg B.B. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 17 5 (2005) 378-384